Prochlorperazine Maleate NDC 72603-169

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-169Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0169Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-169-01	72603016901	100 TABLET in 1 BOTTLE (72603-169-01)Marketed from Sep 7, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prochlorperazine Maleate
Generic name (nonproprietary): prochlorperazine maleate
Active ingredients: Prochlorperazine maleate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Northstar Rx LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 216202
Marketing start: Sep 7, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Phenothiazines (Chemical structure)
Identifiers: Product ID 72603-169_2dda6392-975a-4d77-e063-6294a90a2f67SPL ID 2dda6392-975a-4d77-e063-6294a90a2f67SPL set ID 04bf8a16-218a-c648-e063-6294a90a1afbRxCUI 198365, 312635UNII I1T8O1JTL6
Pharmacologic class: Phenothiazine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603016901 followed by a unit qualifier and the quantity

Package 72603-0169-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 11, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS & USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dy…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 216202

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 216202
Product	Strength	Form · route	Labeler	Product NDC
Prochlorperazine Maleate	Prochlorperazine maleate 5 mg/1	Tablet, Film coatedOral	Major Pharmaceuticals	0904-7381
Prochlorperazine Maleate	Prochlorperazine maleate 10 mg/1	Tablet, Film coatedOral	ANI Pharmaceuticals, Inc.	70954-689
Prochlorperazine Maleate	Prochlorperazine maleate 5 mg/1	Tablet, Film coatedOral	ANI Pharmaceuticals, Inc.	70954-688
Prochlorperazine Maleate	Prochlorperazine maleate 10 mg/1	Tablet, Film coatedOral	Major Pharmaceuticals	0904-7382